KR102389240B1 - 면역-종양 살상 요법 - Google Patents

면역-종양 살상 요법 Download PDF

Info

Publication number
KR102389240B1
KR102389240B1 KR1020167006785A KR20167006785A KR102389240B1 KR 102389240 B1 KR102389240 B1 KR 102389240B1 KR 1020167006785 A KR1020167006785 A KR 1020167006785A KR 20167006785 A KR20167006785 A KR 20167006785A KR 102389240 B1 KR102389240 B1 KR 102389240B1
Authority
KR
South Korea
Prior art keywords
virus
trif
tumor
vaccinia virus
deletion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167006785A
Other languages
English (en)
Korean (ko)
Other versions
KR20160044529A (ko
Inventor
스테픈 호워드 토른
Original Assignee
유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 filed Critical 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
Publication of KR20160044529A publication Critical patent/KR20160044529A/ko
Application granted granted Critical
Publication of KR102389240B1 publication Critical patent/KR102389240B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020167006785A 2013-08-22 2014-08-22 면역-종양 살상 요법 Active KR102389240B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361868978P 2013-08-22 2013-08-22
US61/868,978 2013-08-22
PCT/US2014/052308 WO2015027163A1 (en) 2013-08-22 2014-08-22 Immuno-oncolytic therapies

Publications (2)

Publication Number Publication Date
KR20160044529A KR20160044529A (ko) 2016-04-25
KR102389240B1 true KR102389240B1 (ko) 2022-04-20

Family

ID=52484194

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167006785A Active KR102389240B1 (ko) 2013-08-22 2014-08-22 면역-종양 살상 요법

Country Status (28)

Country Link
US (2) US11478518B2 (https=)
EP (3) EP4324918A3 (https=)
JP (3) JP6912199B2 (https=)
KR (1) KR102389240B1 (https=)
CN (1) CN105658795B (https=)
AU (1) AU2014308648B2 (https=)
CA (3) CA3213683A1 (https=)
CY (1) CY1126587T1 (https=)
DK (2) DK3778897T3 (https=)
EA (1) EA037582B1 (https=)
ES (2) ES2847305T3 (https=)
FI (1) FI3778897T3 (https=)
HR (1) HRP20240078T1 (https=)
HU (1) HUE066593T2 (https=)
IL (1) IL243996A0 (https=)
LT (1) LT3778897T (https=)
MD (2) MD4624C1 (https=)
MX (1) MX2016002257A (https=)
NZ (1) NZ716825A (https=)
PE (1) PE20160673A1 (https=)
PH (1) PH12016500329A1 (https=)
PL (1) PL3778897T3 (https=)
PT (1) PT3778897T (https=)
RS (1) RS65104B1 (https=)
SG (1) SG11201600960PA (https=)
SI (1) SI3778897T1 (https=)
SM (1) SMT202400047T1 (https=)
WO (1) WO2015027163A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65104B1 (sr) * 2013-08-22 2024-02-29 Univ Pittsburgh Commonwealth Sys Higher Education Onkolitičke imunoterapije
CN115300622A (zh) 2015-02-25 2022-11-08 纪念斯隆-凯特琳癌症中心 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
WO2017014296A1 (ja) * 2015-07-22 2017-01-26 国立大学法人鳥取大学 ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子
WO2017043815A1 (en) * 2015-09-08 2017-03-16 Sillajen, Inc. Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof
WO2017079746A2 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
KR20180133395A (ko) 2016-02-25 2018-12-14 메모리얼 슬로안 케터링 캔서 센터 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스
CN109152736A (zh) * 2016-03-25 2019-01-04 联邦高等教育系统匹兹堡大学 合成包封病毒
EP3254692A1 (en) * 2016-06-10 2017-12-13 Ceva Sante Animale Multivalent recombinant spv
CA3070146A1 (en) * 2016-07-19 2018-01-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic viruses targeting stat3
AU2017332367B2 (en) * 2016-09-21 2021-12-23 Stephen H. Thorne High mobility group box i mutant
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
JP7724601B2 (ja) 2017-02-03 2025-08-18 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 腫瘍溶解性ウイルス療法
EP3593136A1 (en) * 2017-03-06 2020-01-15 Talaris Therapeutics, Inc. Methods and compositions for determining the potency of a therapeutic cellular composition
EP4286009A3 (en) * 2017-04-21 2024-04-03 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
EP3703723A4 (en) 2017-10-31 2021-12-15 KaliVir Immunotherapeutics, Inc. ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION
CA3082961A1 (en) 2017-12-01 2019-06-06 Gerd Sutter Immuno-modulated replication-efficient vaccinia virus strain
SG11202006457YA (en) 2018-01-05 2020-08-28 Ottawa Hospital Res Inst Modified orthopoxvirus vectors
WO2020036635A2 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
WO2020018996A2 (en) * 2018-07-20 2020-01-23 Ansun Biopharma, Inc. Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
MX2021003013A (es) 2018-09-15 2021-08-11 Memorial Sloan Kettering Cancer Center Poxvirus recombinantes para inmunoterapia contra cáncer.
EP3898997A4 (en) * 2018-12-21 2022-11-16 Ottawa Hospital Research Institute MODIFIED ORTHOPOXVIRUS VECTORS
CA3125020A1 (en) * 2019-01-07 2020-07-16 Kalivir Immunotherapeutics, Inc. Methods of treating cancer
TW202038994A (zh) * 2019-01-14 2020-11-01 美商醫格耐免疫治療公司 重組痘瘡病毒及其使用方法
WO2020165730A1 (en) 2019-02-14 2020-08-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
CA3150829A1 (en) * 2019-08-26 2021-03-04 Bionoxx Inc. Pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredient for treatment of cancer
KR20220082025A (ko) * 2019-10-16 2022-06-16 칼리버 임뮤노쎄라퓨틱스, 인크. 변형된 세포외 외피보유 바이러스
EP4061417A4 (en) * 2019-11-20 2023-10-11 University of Pittsburgh - of the Commonwealth System of Higher Education VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2021116943A1 (en) * 2019-12-12 2021-06-17 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
WO2021140435A1 (en) * 2020-01-09 2021-07-15 Pfizer Inc. Recombinant vaccinia virus
KR20220152250A (ko) * 2020-03-06 2022-11-15 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 암을 치료하기 위한 irf 모듈레이터를 발현하는 종양용해성 바이러스
US20230355804A1 (en) * 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
TW202227621A (zh) 2020-11-19 2022-07-16 美商凱立凡爾免疫治療股份有限公司 重塑腫瘤微環境的溶瘤免疫療法
BR112023022681A2 (pt) 2021-04-30 2024-01-23 Kalivir Immunotherapeutics Inc Vírus oncolíticos para expressão modificada de mhc
AU2022303363A1 (en) * 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도
IL318055A (en) * 2022-07-08 2025-02-01 Viromissile Inc ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF
WO2025251079A1 (en) * 2024-05-31 2025-12-04 University Of Massachusetts Rna compositions and methods of use thereof in the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9305855A (es) 1992-09-24 1995-01-31 Tadatsugu Taniguchi Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.
WO2000073479A1 (en) 1999-05-28 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
WO2002064159A1 (fr) 2001-02-07 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Remedes contre les tumeurs affectant les organes hematopoietiques
KR20120002613A (ko) * 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
JPWO2007023725A1 (ja) * 2005-08-25 2009-02-26 公立大学法人横浜市立大学 遺伝子ワクチン
US8980246B2 (en) * 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
AU2012244210B2 (en) * 2005-09-07 2014-10-02 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
US20110038843A1 (en) * 2008-03-31 2011-02-17 Kusmartsev Sergei A Tumor Growth Inhibition Via Conditioning of Tumor Microenvironment
ES2848650T3 (es) 2009-09-14 2021-08-11 Sillajen Biotherapeutics Inc Terapia combinada contra el cáncer con virus vaccinia oncolítico
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
ES2733211T3 (es) * 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
US20150250837A1 (en) * 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
RS65104B1 (sr) 2013-08-22 2024-02-29 Univ Pittsburgh Commonwealth Sys Higher Education Onkolitičke imunoterapije

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH. 2001, vol. 61, no. 24, pages 8751-8757.*
Cytokine. 2011, vol. 56, no. 1, page 84.
VIROLOGY. 1977, vol. 78, no. 1, pages 315-322.

Also Published As

Publication number Publication date
HRP20240078T1 (hr) 2024-03-29
JP6912199B2 (ja) 2021-08-04
JP2016527920A (ja) 2016-09-15
JP2019205451A (ja) 2019-12-05
DK3036329T3 (da) 2021-01-11
JP7333431B2 (ja) 2023-08-24
EP3036329B1 (en) 2020-10-07
ES2847305T3 (es) 2021-08-02
IL243996A0 (en) 2016-04-21
AU2014308648A1 (en) 2016-03-03
US12514888B2 (en) 2026-01-06
PT3778897T (pt) 2024-02-01
RS65104B1 (sr) 2024-02-29
FI3778897T3 (fi) 2024-01-25
CY1126587T1 (el) 2026-02-25
JP2022062171A (ja) 2022-04-19
HUE066593T2 (hu) 2024-08-28
CA2921041A1 (en) 2015-02-26
EP3036329A1 (en) 2016-06-29
US11478518B2 (en) 2022-10-25
MD4624B1 (ro) 2019-03-31
EA201690444A1 (ru) 2016-08-31
DK3778897T3 (da) 2024-01-29
EP3778897B1 (en) 2023-12-20
EP4324918A2 (en) 2024-02-21
HK1223402A1 (zh) 2017-07-28
NZ716825A (en) 2022-02-25
US20230008089A1 (en) 2023-01-12
MD4624C1 (ro) 2019-10-31
LT3778897T (lt) 2024-02-12
WO2015027163A9 (en) 2016-04-14
PE20160673A1 (es) 2016-07-21
CA3213683A1 (en) 2015-02-26
CN105658795B (zh) 2020-07-03
US20160235793A1 (en) 2016-08-18
CA2921041C (en) 2023-10-31
CN105658795A (zh) 2016-06-08
MD20160027A2 (ro) 2016-08-31
MD20180086A2 (ro) 2019-03-31
EP4324918A3 (en) 2024-04-24
EP3036329A4 (en) 2017-08-02
EP3778897A1 (en) 2021-02-17
MD4748C1 (ro) 2021-09-30
WO2015027163A1 (en) 2015-02-26
CA3213715A1 (en) 2015-02-26
AU2014308648B2 (en) 2020-11-12
MX2016002257A (es) 2016-11-08
PL3778897T3 (pl) 2024-04-02
SI3778897T1 (sl) 2024-03-29
MD4748B1 (ro) 2021-02-28
PH12016500329A1 (en) 2016-05-02
ES2971528T3 (es) 2024-06-05
JP7021154B2 (ja) 2022-02-16
KR20160044529A (ko) 2016-04-25
SMT202400047T1 (it) 2024-03-13
EA037582B1 (ru) 2021-04-16
SG11201600960PA (en) 2016-03-30

Similar Documents

Publication Publication Date Title
US12514888B2 (en) Immuno-oncolytic therapies
AU2014308648A2 (en) Immuno-oncolytic therapies
US20250332208A1 (en) Oncolytic virus therapy
JP7025339B2 (ja) 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
CN116162654A (zh) 用于癌症免疫疗法的重组痘病毒
KR20200026894A (ko) 개인 맞춤형 백신
CN114786715A (zh) 痘苗病毒和使用痘苗病毒的方法
HK40104741A (en) Immuno-oncolytic therapies
HK40045119A (en) Immuno-oncolytic therapies
HK40045119B (en) Immuno-oncolytic therapies
HK1223402B (zh) 免疫溶瘤療法
US12611444B2 (en) IL-36 cytokine expressing oncolytic viruses for treating cancer
HK40088792A (zh) 用於癌症免疫疗法的重组痘病毒

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160315

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190822

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200713

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200713

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210128

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200914

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190822

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210408

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20220123

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20210907

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210302

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210128

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200914

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190822

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220418

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220418

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250317

Start annual number: 4

End annual number: 4